In a UK digital program, women lost 15.5% of weight in six months

Eight thousand women, one digital platform, six months. Between November 2024 and January 2025, 8,127 women in the UK enrolled in a program delivering GLP-1 receptor agonist therapy, and they had begun treatment by February 2025. Six months later, 7,297 of them had a paired weight measurement, and among those the average loss was 16.1 kg, or 15.5% of starting weight.

The program was run as a structured digital service, and the women paid for it themselves; the provider partly subsidized it during the study. 99.8% of participants were on tirzepatide, a GLP-1 receptor agonist therapy. The group started with a mean body mass index of 38.2, and 88.0% of participants were white. The authors set their results beside those of randomized clinical trials and describe the mean weight reduction as comparable.

Retention was 91.4% at six months, and the authors report no serious treatment-related adverse events. The spread is wide: among the weighed participants, 83.1% lost at least 10% of their weight and 22.4% lost at least 20%. These are shares of the 7,297 weighed women, not of all 8,127 who began.

The design is observational. There is no comparator group, the participants pay for their care, and follow-up stops at six months. The paper names these limits itself, and they bound the conclusions: the figures describe what happened to these women in this service, not what a randomized trial would have shown in them.

For providers who run digital weight-loss programs, the study adds a six-month record on more than eight thousand patients treated outside a trial, with results the authors judge comparable to trial figures. For a paying adult who resembles this cohort, the study offers six-month figures from a real service rather than from a trial. For other groups, the paper reports no outcomes, and whether the gains hold beyond six months is not reported.